Published in
Wiley, British Journal of Dermatology, 5(181), p. 967-975, 2019
DOI: 10.1111/bjd.17919
Links
Tools
Adalimumab medium‐term dosing strategy in moderate‐to‐severe hidradenitis suppurativa: integrated results from the phase III randomized placebo‐controlled PIONEER trials
Journal article published in 2019 by
G. B. E. Jemec 
,
M. M. Okun,
S. B. Forman,
W. P. F. Gulliver,
E. P. Prens,
U. Mrowietz ,
A. W. Armstrong ,
Z. Geng,
Y. Gu,
D. A. Williams,
H. D. Teixeira,
A. B. Kimball
,
M. M. Okun,
S. B. Forman,
W. P. F. Gulliver,
E. P. Prens,
U. Mrowietz ,
A. W. Armstrong ,
Z. Geng,
Y. Gu,
D. A. Williams,
H. D. Teixeira,
A. B. Kimball
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 